Re-exposing Patients to Heparin After Heparin-Induced Thrombocytopenia – JTH
Journal of Thrombosis and Haemostasis (JTH) shared a post on LinkedIn about a recent article by Elizabeth B. Caudill et al., adding:
”Heparin re-exposure in patients with a history of heparin-induced thrombocytopenia
This single-center retrospective study followed 35 patients with prior heparin-induced thrombocytopenia who were re-exposed to heparin products.
Only one (2.9 percent) developed recurrent HIT, with no associated thrombosis, bleeding, or in-hospital mortality. Median interval from HIT diagnosis to re-exposure was 8.1 years, suggesting re-exposure may be safe in remote HIT.”
Title: Heparin re-exposure in patients with a history of heparin-induced thrombocytopenia
Authors: Elizabeth B. Caudill, Ju Hee Kim, Dareen M. Kanaan, Katelyn W. Sylvester, Liriany Y. Pimentel, Christine S. Kim, Jean M. Connors
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 7, 2026, 18:36Richard Kollen: Preventing Deep Vein Thrombosis During Long Flights
-
Sep 7, 2026, 18:34Mahmoud Hashem: Apixaban – Doses According to the Reason for Use
-
Sep 7, 2026, 14:44Abdel Gaffar Mohammed: Treatment Approaches for Different Types of TMA
-
Sep 7, 2026, 18:31Julian P. Villacastin: LAAC as a Treatment Option When Long-Term Anticoagulation Is Problematic
-
Sep 7, 2026, 18:29Geoff Stooke: How Hemophilia Led the Massie Family to the Romanovs and Ronald Reagan
-
Sep 7, 2026, 18:27Sam Mbunya: September is Sickle Cell Awareness Month
-
Sep 7, 2026, 18:25David Akande: Things I Wish People Knew About Sickle Cell
-
Sep 7, 2026, 18:24Prachi Bansal: A Small Act of Giving, A Lifelong Lesson in Humanity
-
Sep 7, 2026, 17:27Isaac Okello: From Global Dialogue to Local Impact in Sickle Cell Disease